Grifols (NASDAQ:GRFS) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Grifols from hold to buy, adding a more bullish note to the stock’s analyst coverage.
• Despite the upgrade, broader analyst sentiment remains cautious: Grifols still has a consensus Hold rating and an average target price of $10.00.
• The stock rose 0.5% to $8.10 while the company reported quarterly EPS of $0.38 on $2.32 billion in revenue, and analysts expect $1.16 EPS for the full year.

Grifols (NASDAQ:GRFS - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Sunday.

Other analysts have also issued research reports about the company. Zacks Research raised Grifols from a "strong sell" rating to a "hold" rating in a report on Friday, February 6th. Weiss Ratings raised Grifols from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Friday. Four analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $10.00.

Grifols Stock Up 0.5%

Shares of NASDAQ:GRFS opened at $8.10 on Friday. The firm has a fifty day moving average of $8.23 and a 200 day moving average of $8.78. The firm has a market capitalization of $5.51 billion, a PE ratio of 42.63, a price-to-earnings-growth ratio of 0.25 and a beta of 0.68. Grifols has a 52-week low of $7.09 and a 52-week high of $11.14. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.88 and a current ratio of 2.51.

Grifols (NASDAQ:GRFS - Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. The company had revenue of $2.32 billion during the quarter. Grifols had a return on equity of 6.23% and a net margin of 5.34%. As a group, research analysts anticipate that Grifols will post 1.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Grifols

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in shares of Grifols by 31.8% during the third quarter. JPMorgan Chase & Co. now owns 2,488,294 shares of the biotechnology company's stock worth $24,783,000 after purchasing an additional 600,118 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Grifols by 5.6% in the 3rd quarter. New York State Common Retirement Fund now owns 2,589,406 shares of the biotechnology company's stock worth $25,790,000 after purchasing an additional 136,678 shares during the period. AdvisorShares Investments LLC purchased a new stake in Grifols during the 3rd quarter valued at approximately $1,012,000. Integrated Quantitative Investments LLC bought a new stake in shares of Grifols during the third quarter valued at approximately $1,361,000. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of Grifols by 80.2% in the third quarter. Envestnet Asset Management Inc. now owns 515,853 shares of the biotechnology company's stock worth $5,138,000 after buying an additional 229,661 shares in the last quarter.

Grifols Company Profile

Grifols, Inc NASDAQ: GRFS is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.